Top news of the day from across the health care landscape
Dallas Cowboys All Pro offensive linemen Travis Frederick announced he was diagnosed with Guillain Barre Syndrome, a rare autoimmune disease, Newsweek reported. According to the article, Frederick said he was receiving treatment for the illness, but did not indicate when he would return to the field. Guillain Barre Syndrome is thought to be triggered by a form of bacteria often found in undercooked poultry, and although there is no known cure for the disease, it can be treated, the article reported.
The World Health Organization said the number of measles cases in Europe increased sharply during the first 6 months of 2018, causing at least 37 deaths, the Associated Press reported. According to the article, the UN agency’s European office said more than 41,000 measles cases were reported during the first half of the year, which is more cases than in all 12-month periods over the past decade. The previous highest annual total was 23,927 cases in 2017, the article reported.
Pfizer Inc and Astellas Pharma Inc are planning to change protocols for 2 late-stage clinical trials testing prostate cancer drug Xtandi to speed up results, Reuters reported. According to the article, the companies said they expect the ARCHES trial to end late this year and the EMBARK trial to be completed by mid-2020, earlier than previous goals. Both trials are testing the drug in men with hormone-sensitive prostate cancer, the article reported.